
Bremelanotide — FDA-approved melanocortin agonist for female sexual dysfunction. Acts via CNS, not vascular like PDE5 inhibitors.
Ranges cited in research literature. Not a usage recommendation. For research use only.
PT-141, international nonproprietary name bremelanotide, is a cyclic heptapeptide — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH — that differs from Melanotan II only at the C-terminus: a free carboxylic acid instead of the amide. It was identified as the active metabolite of Melanotan II after spontaneous erections were observed in that compound's tanning trials, and Palatin Technologies developed it as a centrally acting melanocortin agonist.
It acts mainly on the MC4R receptor in the hypothalamus, with affinity also for MC3R and little action at MC1R, so its pigmentary effect is far smaller than Melanotan II's. Unlike phosphodiesterase inhibitors it does not act on blood flow but on the central dopaminergic pathways of desire and arousal, which made it the first molecule of its class. Its half-life is about 2.7 hours.
Two Phase 3 trials (the RECONNECT program, more than 1,200 women) led to FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women; in men development was halted over the transient rise in blood pressure. The most frequent adverse effects in trials were nausea (around 40%), flushing, headache and, with repeated use, focal hyperpigmentation. Renova's product is not Vyleesi: it is PT-141 for research, not suitable for human use.
| Class | Centrally acting melanocortin agonist (MC4R > MC3R), cyclic α-MSH analog |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (7 aa; differs from MT-II at the C-terminus) |
| CAS | 189691-06-3 |
| Origin | Metabolite of Melanotan II; developed by Palatin Technologies |
| Reported half-life | ≈ 2.7 hours (SC route) |
| Phase 3 data | RECONNECT program (> 1,200 participants); FDA approval 2019 as Vyleesi |
| Drug adverse effects | Nausea (≈ 40%), flushing, headache, transient blood-pressure increase, focal hyperpigmentation |
| Regulatory status | Molecule FDA-approved (Vyleesi); Renova product is RUO |
Yes. PT-141 was Palatin's development code and bremelanotide is the international nonproprietary name; Vyleesi is the brand of the medicine the FDA approved in 2019. All refer to the same cyclic heptapeptide. Renova's product is the molecule as research material, not the medicine.
Sildenafil and its analogs act on vascular tissue, increasing blood flow; PT-141 acts in the hypothalamus, on the MC4R receptors involved in the pathways of desire and arousal. They are independent mechanisms, which is why PT-141 was studied in an indication — hypoactive desire — where vasodilators have no effect.
Because of the transient blood-pressure increase that accompanies administration, seen in the initial intranasal trials; the FDA asked for that program to stop and development was redirected to the subcutaneous route and the female indication, which is the one that reached approval.
Far less. Its affinity for MC1R, the melanocyte receptor, is low, although with repeated use in trials focal hyperpigmentation of the face, gums and breasts was described in about 1% of participants. Melanotan II, by contrast, is a potent MC1R agonist and pigmentation is its main effect.
Related reading: PT-141 (Bremelanotide): A Melanocortin Receptor Agonist · Melanotan II: Melanocortin Agonist
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty